More specifically, IL-12 induced Th1 responses against cancers and improved the anti-tumor efficacy of cancer vaccines, DC vaccines, and other cytokines (IL-18 and IL-15).849 Besides, IL-12 gene-modified DCs showed positive clinical response in patients with stage IV melanoma.850. The gene discussed is IL18; the disease is cancer.